NCT07929493
A Study of Ceftobiprole Compared With Standard Antibiotic Treatment in Children With Staphylococcus Aureus Bacteremia (SAB) Infection, Including Right-sided Heart Infection
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Day 1 through last follow-up (LFU) [up to 11 weeks]
Percentage of participants with serious adverse events (SAEs)
Timeframe: Baseline through LFU [up to 11 weeks]
Percentage of participants with treatment-related adverse events (AEs)
Timeframe: Day 1 through LFU [up to 11 weeks]
Percentage of participants with adverse events of special interest (AESIs)
Timeframe: Baseline through LFU [up to 11 weeks]
Percentage of participants with adverse events (AEs) leading to discontinuation of study-drug treatment
Timeframe: Baseline through LFU [up to 11 weeks]
Percentage of participants with treatment-emergent abnormal hematology laboratory test results
Timeframe: Baseline through the end-of-treatment (EOT) visit [up to approximately 6 weeks]
Percentage of participants with treatment-emergent abnormal blood chemistry laboratory test results
Timeframe: Baseline through the EOT visit [up to approximately 6 weeks]
Percentage of participants with treatment-emergent abnormal urinalysis test results
Timeframe: Baseline through the EOT visit [up to approximately 6 weeks]
Change from baseline in body temperature
Timeframe: Baseline through LFU visit [up to 11 weeks]
Change from baseline in systolic blood pressure
Timeframe: Baseline through LFU visit [up to 11 weeks]
Change from baseline in diastolic blood pressure
Timeframe: Baseline through LFU visit [up to 11 weeks]
Change from baseline in respiratory rate
Timeframe: Baseline through LFU visit [up to 11 weeks]
Change from baseline in heart rate
Timeframe: Baseline through LFU visit [up to 11 weeks]
Secondary (6)
Percentage of All-Cause Mortality (ACM)
Percentage of new metastatic foci or other complications of SAB
Percentage of participants with Clinical Success at the TOC Visit
Percentage of participants with Microbiological Success at the TOC Visit
Percentage of participants with Overall Success at the TOC Visit
Show 1 moreShow less
Ceftobiprole Plasma Concentration
Arms and interventions
CeftobiproleExperimental
Participants randomized to this arm will receive intravenous (IV) ceftobiprole.
Standard-of-Care (SOC)Active comparator
Participants randomized to this arm will receive intravenous (IV) standard-of-care (SOC) antibiotic treatment selected according to local guidelines or site-specific standard practice.
Drugs: Ceftobiprole medocaril sodium, Standard of Care (SOC)